

# A Novel Once-Daily Treatment for Adults with Tardive Dyskinesia

**Presented By:**

Michael Asbach, PA  
Neuropsychiatric Physician Assistant  
DENT Neurologic Institute  
BUFFALO, NY

**Date:**

Tuesday, 6/12/2018 6:30 PM Central

**Location:**

Bob's Steak and Chop House  
301 Lavaca St.  
Austin, TX  
78701

**Please RSVP to your Neurocrine Representative,  
Kristine Brown at [kbrown@neurocrine.com](mailto:kbrown@neurocrine.com) or by 6/10/2018.**

## **INDICATION & USAGE**

INGREZZA (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

## **SELECTED IMPORTANT SAFETY INFORMATION**

The most common adverse reaction ( $\geq 5\%$  and twice the rate of placebo) is somnolence.

**Please see full Important Safety Information on the following page.**

## **IMPORTANT SAFETY INFORMATION**

### **WARNINGS & PRECAUTIONS**

#### **Somnolence**

INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

#### **QT Prolongation**

INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

### **ADVERSE REACTIONS**

The most common adverse reaction ( $\geq 5\%$  and twice the rate of placebo) is somnolence. Other adverse reactions ( $\geq 2\%$  and  $>$ Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

**Please see attached INGREZZA full Prescribing Information or visit [www.INGREZZA.com/HCP](http://www.INGREZZA.com/HCP)**

*This is a promotional program sponsored by Neurocrine Biosciences, Inc., and no CME credits are offered.*